Company: CERO
Filing Date: 2025-01-23
Form Type: 424B3
Source: 0001213900-25-005623
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-23
Form: 424B3
Chunk 2
---
 if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities 
 Act (17 CFR 230.425)                                             |

| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange 
 Act (17 CFR 240.14a-12)                                        |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) 
 under the Exchange Act (17 CFR 240.14d-2(b))              |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) 
 under the Exchange Act (17 CFR 240.13e-4(c))              |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 17, 2025, CERo
Therapeutics Holdings, Inc. (the “Company”) received a letter setting forth the determination of a panel convened by Nasdaq
(the “Nasdaq Panel”) granting the Company’s request for an extension (the “Extension”) to regain compliance
with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025 (the “Extension Date”). The Company
presented its plan (the “Plan”) for regaining compliance with such requirements at a hearing conducted on December 17, 2025.

As previously disclosed, the
Company has not been in compliance with the $50 million